|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM364402113 |
| 003 |
DE-627 |
| 005 |
20240202232040.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202307817
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1278.xml
|
| 035 |
|
|
|a (DE-627)NLM364402113
|
| 035 |
|
|
|a (NLM)37948543
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Yan, Junjie
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Activating Tumor-Selective Liquid Metal Nanomedicine through Galvanic Replacement
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 02.02.2024
|
| 500 |
|
|
|a Date Revised 02.02.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2023 Wiley-VCH GmbH.
|
| 520 |
|
|
|a Advanced chemotherapeutic strategies including prodrug and nanocatalytic medicine have significantly advanced tumor-selective theranostics, but delicate prodrug screening, tedious synthesis, low degradability/biocompatibility of inorganic components, and unsatisfied reaction activity complicate treatment efficacies. Here, the intrinsic anticancer bioactivity of liquid metal nanodroplets (LMNDs) is explored through galvanic replacement. By utilizing a mechano-degradable ligand, the resultant size of the aqueous LMND is unexpectedly controlled as small as ≈20 nm (LMND20). It is demonstrated that LMND20 presents excellent tumor penetration and biocompatibility and activates tumor-selective carrier-to-drug conversion, synchronously depleting Cu2+ ions and producing Ga3+ ions through galvanic replacement. Together with abundant generation of reactive oxygen species, multiple anticancer pathways lead to selective apoptosis and anti-angiogenesis of breast cancer cells. Compared to the preclinical/clinical anticancer drugs of tetrathiomolybdate and Ga(NO3 )3 , LMND20 administration significantly improves the therapeutic efficacy and survival in a BCap-37 xenograft mouse model, yet without obvious side effects
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a cancer therapy
|
| 650 |
|
4 |
|a copper depletion
|
| 650 |
|
4 |
|a drug delivery
|
| 650 |
|
4 |
|a galvanic replacement
|
| 650 |
|
4 |
|a liquid metal
|
| 650 |
|
4 |
|a nanomedicine
|
| 650 |
|
7 |
|a Antineoplastic Agents
|2 NLM
|
| 650 |
|
7 |
|a Prodrugs
|2 NLM
|
| 650 |
|
7 |
|a Metals
|2 NLM
|
| 650 |
|
7 |
|a Ions
|2 NLM
|
| 700 |
1 |
|
|a Wang, Jinqiang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Xinyu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pan, Donghui
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Su, Chen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Junxia
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Mengzhen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xiong, Jianjun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Yu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Lizhen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xu, Yuping
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Chongyang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yang, Min
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gu, Zhen
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 36(2024), 5 vom: 01. Feb., Seite e2307817
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:36
|g year:2024
|g number:5
|g day:01
|g month:02
|g pages:e2307817
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202307817
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 36
|j 2024
|e 5
|b 01
|c 02
|h e2307817
|